Volume Alert - ARNA 4.20 Arena Pharmaceuticals $AR
Post# of 144482
Posted On: 11/19/2014 2:06:29 PM
Volume Alert - ARNA 4.20 Arena Pharmaceuticals $ARNA Hit a high today of 4.32 Closing the day 10:30 at 4.20 -0.11 -2.55% With a day low of 4.19 and a total volume of 1,305,331.
ARNA Recent Posts: http://investorshangout.com/Arena-Pharmaceuti...RNA-53369/
ARNA Arena Pharmaceuticals Recent Headline News
Technical Updates on Biotech Stocks - ImmunoGen, Lexicon Pharma, ZIOPHARM Oncology, Arena Pharma, and Regulus Therapeutics
PR Newswire - Wed Nov 19, 7:40AM CST
Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regulus Therapeutics Inc. (NASDAQ: RGLS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, November 18, 2014, the NASDAQ Composite ended at 4,702.44, up 0.67%, the Dow Jones Industrial Average advanced 0.23%, to finish the day at 17,687.82, and the S&P 500 closed at 2,051.80, up 0.51%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 793.40, up 1.58%, with the index also advancing 12.08% in the last one month. Register for your complimentary reports on these five stocks at:
ZIOP: 3.66 (-0.06), LXRX: 1.27 (-0.02), IMGN: 9.50 (-0.18), RGLS: 16.63 (-1.49), ARNA: 4.10 (-0.21)
Arena Pharmaceuticals' (ARNA) Presents at Stifel Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Tue Nov 18, 10:42AM CST
ARNA: 4.10 (-0.21)
Janssen Is Working Its Way Toward Anti-Obesity
Spencer Osborne - at Seeking Alpha - Mon Nov 17, 4:14PM CST
ZFGN: 20.42 (-0.23), OREX: 5.70 (+0.08), NVO: 44.69 (+0.47), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)
EnteroMedics May Enter The Obesity Space - What Does It Mean?
Spencer Osborne - at Seeking Alpha - Mon Nov 17, 3:43PM CST
OREX: 5.70 (+0.08), ETRM: 1.31 (+0.01), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)
For This Obesity Drug, Europe Trumps the U.S.
Brian Orelli, The Motley Fool - Motley Fool - Mon Nov 17, 3:00PM CST
The launch of Orexigen Therapeutics ' obesity drug Contrave isn't off to the best start. As Chief Commercial Officer Mark Booth put it during the company's latest conference call: Unfortunately, like many new tactics, there have been some...
OREX: 5.70 (+0.08), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)
Belviq Weekly Sales Come In Flat
Spencer Osborne - at Seeking Alpha - Fri Nov 14, 3:58PM CST
ARNA: 4.10 (-0.21)
Belviq For Smoking Cessation - Sizzle Or Smolder?
Spencer Osborne - at Seeking Alpha - Fri Nov 14, 9:24AM CST
ARNA: 4.10 (-0.21)
ARNA Management And Investors Underestimating The Potential Of Belviq And Phentermine Combination
Lance Brofman - at Seeking Alpha - Thu Nov 13, 8:52AM CST
OREX: 5.70 (+0.08), HLF: 38.87 (+0.55), NVO: 44.69 (+0.47), VVUS: 3.07 (+0.03), AMGN: 162.65 (+0.41), GSK: 46.38 (+0.10), ARNA: 4.10 (-0.21)
Arena Pharmaceuticals to Present at Stifel 2014 Healthcare Conference
PR Newswire - Thu Nov 13, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time), at The New York Palace Hotel in New York.
ARNA: 4.10 (-0.21)
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 6:27AM CST
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue?
ARNA: 4.10 (-0.21)
Arena Pharmaceuticals' (ARNA) Presents at Credit Suisse Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Wed Nov 12, 9:32PM CST
ARNA: 4.10 (-0.21)
Bel-Phen Pilot Study News, Hold On To Your Shares
Rx Stocks - at Seeking Alpha - Tue Nov 11, 12:13PM CST
OREX: 5.70 (+0.08), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)
Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 10:15AM CST
The new generation of diet pills approved by the Food and Drug Administration have stumbled out of the gate. Specifically, Arena Pharmaceuticals ' Belviq and VIVUS 's Qsymia reported a combined 283,000 prescriptions in the third quarter, with...
PFE: 30.36 (-0.23), VVUS: 3.07 (+0.03), GSK: 46.38 (+0.10), ARNA: 4.10 (-0.21)
Why Orexigen Therapeutics, Inc. Stock Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Mon Nov 10, 5:52PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Orexigen Therapeutics , a...
OREX: 5.70 (+0.08), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)
Arena And Vivus Investors Need To Watch Orexigen
Spencer Osborne - at Seeking Alpha - Mon Nov 10, 12:24PM CST
OREX: 5.70 (+0.08), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)
Orexigen rises as weight loss drug review proceeds
AP - Mon Nov 10, 10:02AM CST
NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.
OREX: 5.70 (+0.08), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)
Belviq Sales Dip Slightly - Quarter Is Flat Thus Far
Spencer Osborne - at Seeking Alpha - Fri Nov 07, 12:02PM CST
VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)
Vivus Beats The Street On Milestone Payment For ED Drug
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:59AM CST
OREX: 5.70 (+0.08), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)
Will Belviq Advertising Pick Up Again?
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:55AM CST
VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)
Lorcaserin HCl Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases
PR Newswire - Thu Nov 06, 7:00AM CST
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for lorcaserin HCl will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases, also known as The Liver Meeting®, taking place November 7-11, 2014, in Boston, Massachusetts.
ARNA: 4.10 (-0.21)
ARNA Recent Posts: http://investorshangout.com/Arena-Pharmaceuti...RNA-53369/
ARNA Arena Pharmaceuticals Recent Headline News
Technical Updates on Biotech Stocks - ImmunoGen, Lexicon Pharma, ZIOPHARM Oncology, Arena Pharma, and Regulus Therapeutics
PR Newswire - Wed Nov 19, 7:40AM CST
Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regulus Therapeutics Inc. (NASDAQ: RGLS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, November 18, 2014, the NASDAQ Composite ended at 4,702.44, up 0.67%, the Dow Jones Industrial Average advanced 0.23%, to finish the day at 17,687.82, and the S&P 500 closed at 2,051.80, up 0.51%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 793.40, up 1.58%, with the index also advancing 12.08% in the last one month. Register for your complimentary reports on these five stocks at:
ZIOP: 3.66 (-0.06), LXRX: 1.27 (-0.02), IMGN: 9.50 (-0.18), RGLS: 16.63 (-1.49), ARNA: 4.10 (-0.21)
Arena Pharmaceuticals' (ARNA) Presents at Stifel Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Tue Nov 18, 10:42AM CST
ARNA: 4.10 (-0.21)
Janssen Is Working Its Way Toward Anti-Obesity
Spencer Osborne - at Seeking Alpha - Mon Nov 17, 4:14PM CST
ZFGN: 20.42 (-0.23), OREX: 5.70 (+0.08), NVO: 44.69 (+0.47), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)
EnteroMedics May Enter The Obesity Space - What Does It Mean?
Spencer Osborne - at Seeking Alpha - Mon Nov 17, 3:43PM CST
OREX: 5.70 (+0.08), ETRM: 1.31 (+0.01), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)
For This Obesity Drug, Europe Trumps the U.S.
Brian Orelli, The Motley Fool - Motley Fool - Mon Nov 17, 3:00PM CST
The launch of Orexigen Therapeutics ' obesity drug Contrave isn't off to the best start. As Chief Commercial Officer Mark Booth put it during the company's latest conference call: Unfortunately, like many new tactics, there have been some...
OREX: 5.70 (+0.08), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)
Belviq Weekly Sales Come In Flat
Spencer Osborne - at Seeking Alpha - Fri Nov 14, 3:58PM CST
ARNA: 4.10 (-0.21)
Belviq For Smoking Cessation - Sizzle Or Smolder?
Spencer Osborne - at Seeking Alpha - Fri Nov 14, 9:24AM CST
ARNA: 4.10 (-0.21)
ARNA Management And Investors Underestimating The Potential Of Belviq And Phentermine Combination
Lance Brofman - at Seeking Alpha - Thu Nov 13, 8:52AM CST
OREX: 5.70 (+0.08), HLF: 38.87 (+0.55), NVO: 44.69 (+0.47), VVUS: 3.07 (+0.03), AMGN: 162.65 (+0.41), GSK: 46.38 (+0.10), ARNA: 4.10 (-0.21)
Arena Pharmaceuticals to Present at Stifel 2014 Healthcare Conference
PR Newswire - Thu Nov 13, 7:00AM CST
Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview and update at the Stifel 2014 Healthcare Conference on Tuesday, November 18, 2014, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time), at The New York Palace Hotel in New York.
ARNA: 4.10 (-0.21)
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 6:27AM CST
Arena Pharmaceuticals (ARNA) Shares March Higher, Can It Continue?
ARNA: 4.10 (-0.21)
Arena Pharmaceuticals' (ARNA) Presents at Credit Suisse Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Wed Nov 12, 9:32PM CST
ARNA: 4.10 (-0.21)
Bel-Phen Pilot Study News, Hold On To Your Shares
Rx Stocks - at Seeking Alpha - Tue Nov 11, 12:13PM CST
OREX: 5.70 (+0.08), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)
Can Arena Pharmaceuticals Inc. Overcome Belviq's Slow Launch?
George Budwell, The Motley Fool - Motley Fool - Tue Nov 11, 10:15AM CST
The new generation of diet pills approved by the Food and Drug Administration have stumbled out of the gate. Specifically, Arena Pharmaceuticals ' Belviq and VIVUS 's Qsymia reported a combined 283,000 prescriptions in the third quarter, with...
PFE: 30.36 (-0.23), VVUS: 3.07 (+0.03), GSK: 46.38 (+0.10), ARNA: 4.10 (-0.21)
Why Orexigen Therapeutics, Inc. Stock Skyrocketed
Sean Williams, The Motley Fool - Motley Fool - Mon Nov 10, 5:52PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Orexigen Therapeutics , a...
OREX: 5.70 (+0.08), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)
Arena And Vivus Investors Need To Watch Orexigen
Spencer Osborne - at Seeking Alpha - Mon Nov 10, 12:24PM CST
OREX: 5.70 (+0.08), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)
Orexigen rises as weight loss drug review proceeds
AP - Mon Nov 10, 10:02AM CST
NEW YORK (AP) — Shares of Orexigen Therapeutics Inc. jumped Monday after the company said a European Union review of its weight loss drug Contrave, which was approved in the U.S. in September, is progressing on schedule.
OREX: 5.70 (+0.08), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)
Belviq Sales Dip Slightly - Quarter Is Flat Thus Far
Spencer Osborne - at Seeking Alpha - Fri Nov 07, 12:02PM CST
VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)
Vivus Beats The Street On Milestone Payment For ED Drug
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:59AM CST
OREX: 5.70 (+0.08), VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)
Will Belviq Advertising Pick Up Again?
Spencer Osborne - at Seeking Alpha - Thu Nov 06, 7:55AM CST
VVUS: 3.07 (+0.03), ARNA: 4.10 (-0.21)
Lorcaserin HCl Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases
PR Newswire - Thu Nov 06, 7:00AM CST
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that data from the Phase 3 clinical trial program for lorcaserin HCl will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases, also known as The Liver Meeting®, taking place November 7-11, 2014, in Boston, Massachusetts.
ARNA: 4.10 (-0.21)
(0)
(0)Scroll down for more posts ▼